Search - tctmd.com

Displaying 1 - 20 of 802

Sort: Relevancy | Date

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2025

Caitlin E. Cox

December 01, 2025

News Opinion CV Team Dispatch

November 2025 Dispatch for the CV Team

L.A. McKeown

November 24, 2025

News Daily News

Long-Awaited CREST-2 Results Bolster Stents for Asymptomatic Carotid Stenosis

Todd Neale

November 21, 2025

News Daily News

Risk Calculators Miss Many Patients Who Present With First MI

Michael O'Riordan

November 21, 2025

News Conference News AHA 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Michael O'Riordan

November 10, 2025

News Daily News

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

Yael L. Maxwell

November 10, 2025

News Conference News AHA 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

Caitlin E. Cox

November 08, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

Presentation TCT 2025

TCT 488: Sex-Based Differences in Cardiovascular Outcomes With Achieved LDL-C <55 mg/dL: A Comparative Cohort Analysis

Presenter: Mehmet Cilingiroglu

October 28, 2025

Presentation TCT 2025

Optimizing PCI Outcomes After ACS: Lipid Modification Therapies - LDL, Lp(a) and Beyond

Presenter: Marc P. Bonaca

October 27, 2025

Presentation TCT 2025

TCT 481: Strike Early, Strike Strong—But Retest Early as Well: Two-Week LDL-C Assessment Accurately Identifies Non-Responders to Triple Oral Lipid-Lowering Therapy in ACS Patients Undergoing PCI

Presenter: Kunal Mahajan

October 27, 2025

Presentation TCT 2025

TCT 470: Comparative Outcomes of Serum LDL Levels <55 mg/dL Versus 55–100 mg/dL for Primary Prevention of Undiagnosed Coronary Artery Disease: A Retrospective Cohort Study

Presenter: Mehmet Cilingiroglu

October 27, 2025

Presentation TCT 2025

TCT 475: Impact of Elevated Lipoprotein(a) on LDL Cholesterol Target Attainment Following PCI for Acute Coronary Syndrome Despite Intensive Triple Oral Lipid-Lowering Therapy: A Retrospective Cohort Study

Presenter: Kunal Mahajan

October 27, 2025

Presentation TCT 2025

ACS Pharma Trials On The Horizon: LDL Lowering Therapies

Presenter: Angelo Oliva

October 26, 2025

News Daily News

Biomarkers Added to a Polygenic Risk Score Equals Better CAD Prediction

Yael L. Maxwell

October 23, 2025

News Daily News

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Caitlin E. Cox

October 03, 2025

Advertisement

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

TCTMD’s Top 10 Most Popular Stories for November 2025

November 2025 Dispatch for the CV Team

Long-Awaited CREST-2 Results Bolster Stents for Asymptomatic Carotid Stenosis

Risk Calculators Miss Many Patients Who Present With First MI

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

TCT 488: Sex-Based Differences in Cardiovascular Outcomes With Achieved LDL-C <55 mg/dL: A Comparative Cohort Analysis

Optimizing PCI Outcomes After ACS: Lipid Modification Therapies - LDL, Lp(a) and Beyond

TCT 481: Strike Early, Strike Strong—But Retest Early as Well: Two-Week LDL-C Assessment Accurately Identifies Non-Responders to Triple Oral Lipid-Lowering Therapy in ACS Patients Undergoing PCI

TCT 470: Comparative Outcomes of Serum LDL Levels <55 mg/dL Versus 55–100 mg/dL for Primary Prevention of Undiagnosed Coronary Artery Disease: A Retrospective Cohort Study

TCT 475: Impact of Elevated Lipoprotein(a) on LDL Cholesterol Target Attainment Following PCI for Acute Coronary Syndrome Despite Intensive Triple Oral Lipid-Lowering Therapy: A Retrospective Cohort Study

ACS Pharma Trials On The Horizon: LDL Lowering Therapies

Biomarkers Added to a Polygenic Risk Score Equals Better CAD Prediction

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content